B cell precursor acute lymphoblastic leukemia (ALL) is the most common form of cancer in children. The leukemic lymphoblasts are clonal expansions of B cell progenitors that grow within the bone marrow microenvironment. The long- term objective of this proposal is to define the in vivo requirements for survival, growth and differentiation of normal and leukemic B lymphoblasts. The culture system described in this application uses bone marrow-derived stromal cells to prevent apoptosis of immature B cells and sustains their growth in vitro. Achievements during the past funding period include the demonstration that direct contact with stroma is required for lymphoid cell survival, and the identification of several molecules involved in this interaction. Additionally, ligation of CD38, a transmembrane glycoprotein abundantly expressed on immature B cells, was found to suppress lymphopoiesis. The information gained has enabled us to develop assays that may improve the treatment of ALL. That is, the growth of leukemic cells on stroma correlated strongly with treatment outcome, providing a means to test sensitivity of leukemic B lymphoblasts to anticancer drugs.
Specific Aim 1 and 2 of this application focus on the microenvironmental signals that regulate B lymphopoiesis. Recognition that ligation of the CD38 molecule inhibits cell growth and induces apoptosis in B-cell precursors has suggested studies to identify the natural ligand of CD38, and to define its tissue distribution and physiological role (Aim 1). As a result of the observation that contact with stroma is essential for immature B-cell survival, experiments have been proposed to identify the stroma-derived molecules that trigger anti-apoptotic signals in such cells (Aim 2). Information that has been gained about survival requirements of leukemic B- cell precursors will be used (in Aim 3) to address an unresolved question of clinical importance: does drug sensitivity testing in vitro have prognostic importance in childhood ALL? By using our stroma-based assay to support the long-term growth of ALL blasts, it should be possible to correlate in vitro cellular responses to different antileukemic drugs with clinicobiologic features of ALL and treatment outcome. This retrospective study banks on the comprehensive information collected on each child enrolled in Total Therapy Study XII, the clinical trial on which the comparison is based. Defining the molecular interactions that regulate normal and leukemic B- cell progenitors should greatly increase our understanding of B-cell ontogeny as well as leukemogenesis. Establishing a drug sensitivity assay with prognostic relevance could lead to improved rationales for drug selection in individual patients with ALL.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Pathology B Study Section (PTHB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Iwamoto, Shotaro; Mihara, Keichiro; Downing, James R et al. (2007) Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117:1049-57
Imai, Chihaya; Iwamoto, Shotaro; Campana, Dario (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376-83
Imai, C; Campana, D (2004) Genetic modification of T cells for cancer therapy. J Biol Regul Homeost Agents 18:62-71
Imai, C; Mihara, K; Andreansky, M et al. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676-84
Mihara, Keichiro; Imai, Chihaya; Coustan-Smith, Elaine et al. (2003) Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 120:846-9
Pui, Ching-Hon; Relling, Mary V; Campana, Dario et al. (2002) Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 6:161-80; discussion 200-2
Pui, Ching Hon; Relling, Mary V; Evans, William E (2002) Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15:741-56
Suzuki, T; Coustan-Smith, E; Mihara, K et al. (2002) Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells. Leukemia 16:1276-84
Ito, C; Tecchio, C; Coustan-Smith, E et al. (2002) The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis. Leukemia 16:1344-52
Srivannaboon, K; Shanafelt, A B; Todisco, E et al. (2001) Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood 97:752-8

Showing the most recent 10 out of 36 publications